Committee voted to ease restrictions on which Medicaid patients can access hepatitis C medications
WASHINGTON, May 18, 2016 – The Alliance for Patient Access’ Hepatitis Therapy Working Group made the following statement on the Pennsylvania Pharmacy and Therapeutics Committee recommendation yesterday to remove barriers to access to a new generation of Hepatitis C cures.
At a hearing yesterday, the Pennsylvania Pharmacy and Therapeutics Committee voted to further ease restrictions on which Medicaid patients can access new hepatitis C treatments, which have a 90 to 99 percent cure rate. The committee’s recommendation would remove restrictions that require patients to have some degree of liver fibrosis (a metavir score of F2 or greater) to gain access to these medications. Last year, the committee also removed a restriction that required Medicaid patients to be completely drug and alcohol free in order to access the medications. Health official subsequently adopted their recommendation.
STATEMENT FROM DR. STACEY TROOSKIN, PENNSYLVANIA PHYSICIAN AND ALLIANCE FOR PATIENT ACCESS MEMBER:
“As a physician who treats hepatitis C patients, I am extremely pleased with the committee’s recommendations that will allow more patients access to treatment. These new medications are game changers for patients suffering with hepatitis C, offering high rates of cure with few side effects. It is my hope that Secretary Dallas will approve the committee’s recommendations and remove access barriers for hepatitis C patients.”
Click HERE for more information.